

Mark S Sulkowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3422872/publications.pdf>

Version: 2024-02-01

246
papers

35,341
citations

8181

76
h-index

3261

185
g-index

248
all docs

248
docs citations

248
times ranked

19217
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 125-135.e8.	4.4	3
2	A prospective cohort study of renal function and bone turnover in adults with hepatitis B virus (<sc>HBV</sc>)-HIV co-infection with high prevalence of tenofovir-based antiretroviral therapy use. <i>HIV Medicine</i> , 2023, 24, 55-74.	2.2	2
3	HBV transcription and translation persist despite viral suppression in HBV-HIV co-infected patients on antiretroviral therapy. <i>Hepatology</i> , 2023, 77, 594-605.	7.3	2
4	Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 256-268.	4.4	34
5	Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs. <i>Journal of Infectious Diseases</i> , 2022, 225, 903-911.	4.0	4
6	Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments. <i>Clinical Infectious Diseases</i> , 2022, 75, 3-10.	5.8	4
7	Validation of a tool to assess effectiveness of peer-recruitment for hepatitis C testing and linkage to care among people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2022, 230, 109177.	3.2	1
8	Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C: An HCV-TARGET analysis. <i>Hepatology</i> , 2022, 76, 483-491.	7.3	16
9	A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360) Tj ETQq1 1 0.784314 rgBT /Overlock 10 7, 307-317.	8.1	39
10	Clostridioides difficile infection (CDI) in a previous room occupant predicts CDI in subsequent room occupants across different hospital settings. <i>American Journal of Infection Control</i> , 2022, 50, 1352-1354.	2.3	5
11	Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	4.4	0
12	Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1169-1178.	3.7	8
13	Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2022, 77, 642-652.	3.7	17
14	Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2022, 77, 1265-1275.	3.7	21
15	Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	22
16	Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2021, 73, e3275-e3285.	5.8	15
17	Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant. <i>American Journal of Transplantation</i> , 2021, 21, 1780-1788.	4.7	14
18	Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study. <i>Annals of Internal Medicine</i> , 2021, 174, 137-138.	3.9	38

#	ARTICLE	IF	CITATIONS
19	Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C. <i>Advances in Therapy</i> , 2021, 38, 423-440.	2.9	23
20	OUP accepted manuscript. <i>Clinical Infectious Diseases</i> , 2021, , .	5.8	0
21	T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab079.	0.9	6
22	Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration. <i>International Journal of Drug Policy</i> , 2021, 88, 103019.	3.3	7
23	Hepatitis B Virus/Hepatitis D Virus Coinfected Liver Transplant Candidate Receiving Hepatitis B Virus-Deoxyribonucleic Acid Positive Allograft and Treated With High-Dose Hepatitis B Immune Globulin. <i>ACG Case Reports Journal</i> , 2021, 8, e00582.	0.4	3
24	Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: An individual patient data meta-analysis. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 1166-1187.	2.4	33
25	A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. <i>Hepatology</i> , 2021, 74, 2952-2964.	7.3	7
26	A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV/HIV Coinfected Adults in North America. <i>Hepatology</i> , 2021, 74, 1174-1189.	7.3	11
27	Impact of co-occurring drug use, hazardous alcohol use and mental health disorders on drug use patterns in people living with HIV and hepatitis C virus infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab520.	0.9	0
28	Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. <i>Advances in Therapy</i> , 2021, 38, 5777-5790.	2.9	9
29	HCV communication within ego-centric networks of men and women who inject drugs. <i>Drug and Alcohol Dependence</i> , 2021, 229, 109157.	3.2	4
30	Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Coinfected Adults. <i>Hepatology</i> , 2020, 71, 411-421.	7.3	23
31	Patient's Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site. <i>AJOB Empirical Bioethics</i> , 2020, 11, 40-52.	1.6	10
32	Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. <i>Lancet HIV</i> , 2020, 7, e443-e448.	4.7	27
33	Unreported alcohol use was common but did not impact hepatitis C cure in HIV-infected persons who use drugs. <i>Journal of Viral Hepatitis</i> , 2020, 27, 476-483.	2.0	5
34	Single Hepatocyte Hepatitis B Virus Transcriptional Landscape in HIV Coinfection. <i>Journal of Infectious Diseases</i> , 2020, 221, 1462-1469.	4.0	18
35	Nurse case management to improve the hepatitis C care continuum in HIV co-infection: Results of a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2020, 27, 376-386.	2.0	9
36	Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1388-1395.	2.0	9

#	ARTICLE	IF	CITATIONS
37	Factors associated with phylogenetic clustering of hepatitis C among people who inject drugs in Baltimore. <i>BMC Infectious Diseases</i> , 2020, 20, 815.	2.9	9
38	Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era. <i>Liver International</i> , 2020, 40, 2407-2416.	3.9	19
39	The Economic Value of Improved Productivity from Treatment of Chronic Hepatitis C Virus Infection: A Retrospective Analysis of Earnings, Work Loss, and Health Insurance Data. <i>Advances in Therapy</i> , 2020, 37, 4709-4719.	2.9	5
40	DÃ©jà vu All Over Again: Retreatment of HCV Direct Acting Antivirals Failuresâ€”Same Satisfactory Results, Same Unanswered Questions. <i>Clinical Infectious Diseases</i> , 2020, 73, e3296-e3299.	5.8	0
41	Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult. <i>Journal of Infectious Diseases</i> , 2020, 222, S745-S757.	4.0	9
42	Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1384-1396.	3.7	19
43	Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 11987-11994.	7.1	15
44	Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virusâ€”HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation. <i>Journal of Infectious Diseases</i> , 2020, 222, 1334-1344.	4.0	7
45	Individual and network factors associated with HCV treatment uptake among people who inject drugs. <i>International Journal of Drug Policy</i> , 2020, 78, 102714.	3.3	19
46	Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care. <i>Journal of Viral Hepatitis</i> , 2020, 27, 663-670.	2.0	18
47	Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy. <i>Journal of Infectious Diseases</i> , 2020, 222, 601-610.	4.0	7
48	Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine. <i>Clinical Infectious Diseases</i> , 2020, 71, 2986-2990.	5.8	7
49	Single hepatocytes show persistence and transcriptional inactivity of hepatitis B. <i>JCI Insight</i> , 2020, 5, .	5.0	17
50	Public Masking: An Urgent Need to Revise Global Policies to Protect against COVID-19. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 102, 1160-1161.	1.4	12
51	The Proof Is in the Patient: Hepatitis C Virus Microelimination in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 577-579.	5.8	4
52	THU-182-The PRIORITIZE study: A pragmatic, randomized study of oral regimens for hepatitis C-transforming decision-making for patients, providers, and stakeholders. <i>Journal of Hepatology</i> , 2019, 70, e242.	3.7	1
53	Hepatitis C-positive donor liver transplantation for hepatitis C seronegative recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13194.	1.7	33
54	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. <i>Gastroenterology</i> , 2019, 157, 1506-1517.e1.	1.3	32

#	ARTICLE	IF	CITATIONS
55	Hepatitis C Elimination in People With HIV Is Contingent on Closing Gaps in the HIV Continuum. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz426.	0.9	14
56	The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infection. <i>Topics in Medicinal Chemistry</i> , 2019, , 97-113.	0.8	5
57	Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ÅŸ2M in the ION-4 Study Cohort. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy273.	0.9	9
58	Advanced liver fibrosis and care continuum in emergency department patients with chronic hepatitis C. <i>American Journal of Emergency Medicine</i> , 2019, 37, 286-290.	1.6	2
59	Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. <i>Journal of Substance Abuse Treatment</i> , 2019, 100, 45-51.	2.8	49
60	A Randomized Controlled Trial of Cash Incentives or Peer Support to Increase HCV Treatment for Persons With HIV Who Use Drugs: The CHAMPS Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz166.	0.9	34
61	Overlapping epidemics of alcohol and illicit drug use among HCV-infected persons who inject drugs. <i>Addictive Behaviors</i> , 2019, 96, 56-61.	3.0	11
62	Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States. <i>American Journal of Transplantation</i> , 2019, 19, 2329-2341.	4.7	35
63	2549. Variance Between Clinicians and Guidelines in Management of HIV/HCV Coinfection. <i>Open Forum Infectious Diseases</i> , 2019, 6, S886-S886.	0.9	0
64	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 746-757.	0.4	33
65	Cigarette Smoking in Persons Living with Hepatitis C: The National Health and Nutrition Examination Survey (NHANES), 1999-2014. <i>American Journal of Medicine</i> , 2018, 131, 669-675.	1.5	21
66	Efficacy and safety of 6 or 8Åweeks of simeprevir, daclatasvir, sofosbuvir for <scp>HCV</scp> genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 631-639.	2.0	10
67	Understanding and addressing hepatitis C reinfection in the oral directÅacting antiviral era. <i>Journal of Viral Hepatitis</i> , 2018, 25, 220-227.	2.0	75
68	Reply. <i>Hepatology</i> , 2018, 67, 1183-1184.	7.3	0
69	Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India. <i>International Journal of Drug Policy</i> , 2018, 57, 51-60.	3.3	7
70	Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. <i>Clinical Infectious Diseases</i> , 2018, 67, 1010-1017.	5.8	125
71	Directly observed therapy of sofosbuvir/ribavirin +/Å peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (CÅ<scp>DOT</scp>). <i>Journal of Viral Hepatitis</i> , 2018, 25, 37-46.	2.0	6
72	Utilization of hepatitis C virus RNAÅpositive donor liver for transplant to hepatitis C virus RNAÅnegative recipient. <i>Liver Transplantation</i> , 2018, 24, 140-143.	2.4	32

#	ARTICLE	IF	CITATIONS
73	Inpatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens. <i>Journal of Viral Hepatitis</i> , 2018, 25, 344-353.	2.0	3
74	A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NAÏVE PATIENTS. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 284-285.	0.3	1
75	Care2Cure: A randomized controlled trial protocol for evaluating nurse case management to improve the hepatitis C care continuum within HIV primary care. <i>Research in Nursing and Health</i> , 2018, 41, 417-427.	1.6	4
76	The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States. <i>Annals of Internal Medicine</i> , 2018, 168, 702.	3.9	169
77	An Education and Field Experience Program to Increase Detection of Human Immunodeficiency Virus and Hepatitis C Virus. <i>Progress in Community Health Partnerships: Research, Education, and Action</i> , 2018, 12, 101-109.	0.3	4
78	Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients. <i>Annals of Internal Medicine</i> , 2018, 168, 533.	3.9	258
79	Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey. <i>Transplant Infectious Disease</i> , 2018, 20, e12982.	1.7	12
80	Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial. <i>Clinical Infectious Diseases</i> , 2018, 66, 1953-1956.	5.8	0
81	Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy. <i>Transplantation</i> , 2018, 102, 2088-2095.	1.0	36
82	Cigarette Smoking Behaviors and Beliefs in Persons Living With Hepatitis C. <i>Nicotine and Tobacco Research</i> , 2017, 19, ntw212.	2.6	9
83	NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. <i>Journal of Hepatology</i> , 2017, 66, 910-918.	3.7	192
84	Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. <i>Hepatology</i> , 2017, 66, 389-397.	7.3	172
85	Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma. <i>Hepatology</i> , 2017, 66, 661-663.	7.3	15
86	Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfecting with HIV and HCV genotype-1: a Phase III, open-label study. <i>Hepatology International</i> , 2017, 11, 188-198.	4.2	2
87	Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1 without cirrhosis. <i>Journal of Hepatology</i> , 2017, 67, 263-271.	3.7	261
88	Patient-reported outcomes in patients coinfected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL5 study. <i>Liver International</i> , 2017, 37, 1796-1804.	3.9	30
89	Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. <i>Hepatology</i> , 2017, 66, 1083-1089.	7.3	75
90	Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. <i>Hepatology</i> , 2017, 66, 1090-1101.	7.3	149

#	ARTICLE	IF	CITATIONS
91	Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. <i>Gut</i> , 2017, 66, 1844-1852.	12.1	69
92	Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era. <i>American Journal of Transplantation</i> , 2017, 17, 519-527.	4.7	95
93	Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease. <i>Clinical Infectious Diseases</i> , 2017, 65, 864-866.	5.8	9
94	High hepatitis C cure rates among black and nonblack human immunodeficiency virus-infected adults in an urban center. <i>Hepatology</i> , 2017, 66, 1402-1412.	7.3	39
95	Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 6-12.	5.8	133
96	Increased Mortality Among Persons With Chronic Hepatitis C With Moderate or Severe Liver Disease: A Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 235-243.	5.8	15
97	Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2017, 166, 637.	3.9	540
98	Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURWARD study). <i>Liver International</i> , 2017, 37, 836-842.	3.9	28
99	Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. <i>Journal of Viral Hepatitis</i> , 2017, 24, 280-286.	2.0	8
100	Response to Cytoplasmic rods and rings in ribavirin and Cytoplasmic rods and rings in mycophenolic acid treatment.. <i>Liver International</i> , 2017, 37, 1743-1744.	3.9	0
101	Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies. <i>Clinical Infectious Diseases</i> , 2017, 64, 44-52.	5.8	89
102	The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection. <i>Journal of Hepatology</i> , 2017, 66, 267-269.	3.7	17
103	Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. <i>Clinical Infectious Diseases</i> , 2017, 64, 92-99.	5.8	18
104	Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx024.	0.9	22
105	Reply to Ozaras et al. <i>Clinical Infectious Diseases</i> , 2017, 64, 1463-1463.	5.8	4
106	Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening. , 2016, 6, .		6
107	Primary Care Providers Knowledge, Attitude and Practices Related to Hepatitis C Screening and Treatment in the Oral Direct Acting Antiviral Agents Era. , 2016, 06, .		18
108	Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. <i>Annals of Hepatology</i> , 2016, 15, 333-349.	1.5	1

#	ARTICLE	IF	CITATIONS
109	About This Continuing Medical Education Activity. <i>Clinical Infectious Diseases</i> , 2016, 63, S1-S2.	5.8	0
110	Interaction Between Alcohol Consumption Patterns, Antiretroviral Therapy Type, and Liver Fibrosis in Persons Living with HIV. <i>AIDS Patient Care and STDs</i> , 2016, 30, 200-207.	2.5	28
111	Public health clinic-based hepatitis C testing and linkage to care in baltimore. <i>Journal of Viral Hepatitis</i> , 2016, 23, 366-374.	2.0	51
112	Serum Fibrosis Markers for the Diagnosis of Liver Disease Among People With Chronic Hepatitis C in Chennai, India. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw156.	0.9	6
113	HCV/HIV co-infected patients: no longer a "special" population?. <i>Liver International</i> , 2016, 36, 43-46.	3.9	26
114	Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. <i>Gastroenterology</i> , 2016, 151, 1131-1140.e5.	1.3	199
115	Morbidity and Mortality Among Community-Based People Who Inject Drugs With a High Hepatitis C and Human Immunodeficiency Virus Burden in Chennai, India. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw121.	0.9	12
116	No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw507.	5.8	58
117	Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 528-531.	5.8	13
118	Senior Center-Based Hepatitis C Screening in Baltimore. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv217.	0.9	6
119	Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, S3-S11.	5.8	49
120	Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1597-1600.	3.0	4
121	Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. <i>Hepatology</i> , 2016, 63, 437-444.	7.3	55
122	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2016, 150, 419-429.	1.3	166
123	Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India. <i>PLoS ONE</i> , 2016, 11, e0147879.	2.5	19
124	Development of sofosbuvir for the treatment of hepatitis C virus infection. <i>Annals of the New York Academy of Sciences</i> , 2015, 1358, 56-67.	3.8	31
125	Immunologic Predictors of Liver Transplantation Outcomes in HIV-HCV Co-Infected Persons. <i>PLoS ONE</i> , 2015, 10, e0135882.	2.5	10
126	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , 2015, 149, 649-659.	1.3	725

#	ARTICLE	IF	CITATIONS
127	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2608-2617.	27.0	740
128	Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. <i>Lancet HIV</i> , 2015, 2, e319-e327.	4.7	285
129	Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. <i>New England Journal of Medicine</i> , 2015, 373, 714-725.	27.0	382
130	Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. <i>New England Journal of Medicine</i> , 2015, 373, 705-713.	27.0	432
131	Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. <i>Hepatology</i> , 2015, 62, 25-30.	7.3	82
132	Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1223.	7.4	290
133	Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1728.	7.4	85
134	Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed. <i>Hepatology</i> , 2015, 62, 129-134.	7.3	23
135	Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. <i>Gastroenterology</i> , 2015, 149, 1345-1360.	1.3	306
136	Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 825-843.	2.2	17
137	Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. <i>Lancet</i> , 2015, 385, 1087-1097.	13.7	257
138	Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. <i>Lancet Infectious Diseases</i> , 2015, 15, 36-45.	9.1	75
139	Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. <i>Hepatology</i> , 2015, 61, 41-45.	7.3	173
140	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , 2015, 64, 948-956.	12.1	101
141	Gastrointestinal, Hepatobiliary, and Pancreatic Manifestations of Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2015, 60, 1567-1573.		1
142	Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis. <i>Open Forum Infectious Diseases</i> , 2014, 1, S42-S42.	0.9	0
143	Sexually Transmitted Diseases Clinic Based Hepatitis C Testing and Linkage to Care. <i>Open Forum Infectious Diseases</i> , 2014, 1, S49-S49.	0.9	1
144	Interferon-Containing and Interferon-Free HCV Therapy for HIV-Infected Patients. <i>Seminars in Liver Disease</i> , 2014, 34, 072-078.	3.6	6

#	ARTICLE	IF	CITATIONS
145	Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfecting adults: Prospective analysis of 435 liver biopsy pairs. <i>Hepatology</i> , 2014, 59, 767-775.	7.3	81
146	Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. <i>Liver International</i> , 2014, 34, 707-719.	3.9	15
147	Management of acute and chronic HCV infection in persons with HIV coinfection. <i>Journal of Hepatology</i> , 2014, 61, S108-S119.	3.7	19
148	Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 353.	7.4	236
149	All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. <i>Hepatology</i> , 2014, 60, 56-64.	7.3	43
150	Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. <i>Hepatology</i> , 2014, 60, 37-45.	7.3	103
151	Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfecting patients. <i>Hepatology</i> , 2014, 60, 477-486.	7.3	14
152	Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2014, 370, 1483-1493.	27.0	1,241
153	Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. <i>New England Journal of Medicine</i> , 2014, 370, 222-232.	27.0	262
154	Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. <i>HIV Medicine</i> , 2014, 15, 108-115.	2.2	28
155	Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 657-675.	3.7	62
156	Interferon-Induced Protein 10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response. <i>Journal of Infectious Diseases</i> , 2014, 210, 1881-1885.	4.0	19
157	Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. <i>Lancet, The</i> , 2014, 384, 1756-1765.	13.7	751
158	Retreatment of HCV with ABT-450/Ombitasvir and Dasabuvir with Ribavirin. <i>New England Journal of Medicine</i> , 2014, 370, 1604-1614.	27.0	536
159	Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2014, 370, 211-221.	27.0	1,065
160	O63 EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/âˆ’ RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY. <i>Journal of Hepatology</i> , 2014, 60, S26.	3.7	12
161	Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. <i>Lancet Infectious Diseases, The</i> , 2013, 13, 597-605.	9.1	175
162	Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. <i>Hepatology</i> , 2013, 57, 2155-2163.	7.3	64

#	ARTICLE	IF	CITATIONS
163	Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial. <i>Hepatology</i> , 2013, 57, 2143-2154.	7.3	102
164	Current Management of Hepatitis C Virus Infection in Patients With HIV Co-infection. <i>Journal of Infectious Diseases</i> , 2013, 207, S26-S32.	4.0	48
165	Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial. <i>Gastroenterology</i> , 2013, 145, 1035-1044.e5.	1.3	51
166	Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics. <i>Antiviral Research</i> , 2013, 99, 214-220.	4.1	28
167	HCV therapy in HIV-infected patients. <i>Liver International</i> , 2013, 33, 63-67.	3.9	30
168	Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. <i>Hepatology</i> , 2013, 57, 974-984.	7.3	67
169	Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. <i>New England Journal of Medicine</i> , 2013, 368, 1867-1877.	27.0	992
170	The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. <i>Journal of Viral Hepatitis</i> , 2013, 20, 745-760.	2.0	78
171	Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV. <i>Annals of Internal Medicine</i> , 2013, 159, 86-96.	3.9	179
172	Relationship of Liver Disease Stage and Antiviral Therapy With Liver-Related Events and Death in Adults Coinfected With HIV/HCV. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 370-8.	7.4	180
173	Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy. <i>Hepatitis Research and Treatment</i> , 2012, 2012, 1-21.	2.0	4
174	Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons. <i>Clinical Infectious Diseases</i> , 2012, 54, 979-983.	5.8	27
175	Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial. <i>HIV Clinical Trials</i> , 2012, 13, 142-152.	2.0	66
176	Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals. <i>Gastroenterology</i> , 2012, 142, 1324-1334.e3.	1.3	78
177	Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir. <i>Gastroenterology</i> , 2012, 143, 608-618.e5.	1.3	179
178	Hepatitis C genotype 1 infection in HIV-Infected patients in the era of direct-acting antiviral therapy. <i>Clinical Liver Disease</i> , 2012, 1, 69-72.	2.1	0
179	Hepatitis C virus-human immunodeficiency virus coinfection. <i>Liver International</i> , 2012, 32, 129-134.	3.9	20
180	HIV Co-Infection Drug Toxicity. , 2012, , 683-699.		1

#	ARTICLE	IF	CITATIONS
181	Hepatitis C: Natural History. , 2012, , 101-105.		0
182	Incidence and Risk Factors for Steatosis Progression in Adults Coinfected With HIV and Hepatitis C Virus. <i>Gastroenterology</i> , 2011, 140, 809-817.	1.3	51
183	Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2011, 365, 1014-1024.	27.0	716
184	Boceprevir for Untreated Chronic HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2011, 364, 1195-1206.	27.0	2,352
185	Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 212-223.	17.8	119
186	Racial differences in hepatitis C treatment eligibility. <i>Hepatology</i> , 2011, 54, 70-78.	7.3	47
187	Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients (SLAM-C). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 597-605.	2.1	26
188	ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. <i>Nature</i> , 2010, 464, 405-408.	27.8	430
189	Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop. <i>American Journal of Gastroenterology</i> , 2010, 105, 989-1004.	0.4	30
190	Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons. <i>Aids</i> , 2010, 24, 811-817.	2.2	9
191	MELD Score Is an Important Predictor of Pretransplantation Mortality in HIV-Infected Liver Transplant Candidates. <i>Gastroenterology</i> , 2010, 138, 159-164.	1.3	77
192	Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate. <i>Gastroenterology</i> , 2010, 139, 1602-1611.e1.	1.3	102
193	Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus. <i>Gastroenterology</i> , 2010, 139, 120-129.e18.	1.3	633
194	Assessment of Liver Fibrosis by Transient Elastography in Persons with Hepatitis C Virus Infection or HIV–Hepatitis C Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2009, 48, 963-972.	5.8	134
195	Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. <i>Nature</i> , 2009, 461, 399-401.	27.8	3,394
196	Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2009, 361, 580-593.	27.0	1,166
197	Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2009, 360, 1827-1838.	27.0	1,038
198	Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. <i>Aids</i> , 2009, 23, 2397-2404.	2.2	55

#	ARTICLE	IF	CITATIONS
199	Viral hepatitis and HIV coinfection. <i>Journal of Hepatology</i> , 2008, 48, 353-367.	3.7	260
200	Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. <i>Aids</i> , 2008, 22, 1399-1410.	2.2	149
201	Management of Hepatic Complications in HIV-Infected Persons. <i>Journal of Infectious Diseases</i> , 2008, 197, S279-S293.	4.0	73
202	The HIV-Coinfected Patient. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, S36-S37.	2.1	10
203	Care of patients coinfecting with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. <i>Aids</i> , 2007, 21, 1073-1089.	2.2	295
204	Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. <i>Aids</i> , 2007, 21, 2209-2216.	2.2	169
205	Therapeutic issues in HIV/HCV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2007, 14, 371-386.	2.0	71
206	Specific targeted antiviral therapy for hepatitis C. <i>Current Gastroenterology Reports</i> , 2007, 9, 5-13.	2.5	19
207	Hepatitis C virus infection in HIV-infected patients. <i>Current Infectious Disease Reports</i> , 2007, 3, 469-476.	3.0	21
208	Treatment algorithm for the management of hepatitis C in HIV-coinfected persons. <i>Journal of Hepatology</i> , 2006, 44, S49-S55.	3.7	20
209	Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. <i>Aids</i> , 2006, 20, 2361-2369.	2.2	121
210	Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. <i>Journal of Viral Hepatitis</i> , 2006, 13, 683-689.	2.0	112
211	Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. <i>Hepatology</i> , 2006, 43, 1317-1325.	7.3	3,343
212	Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness. <i>Aids</i> , 2005, 19, S8-S12.	2.2	17
213	Hepatic steatosis and antiretroviral drug use among adults coinfecting with HIV and hepatitis C virus. <i>Aids</i> , 2005, 19, 585-592.	2.2	158
214	Peginterferon Alfa-2a Does Not Alter the Pharmacokinetics of Methadone in Patients with Chronic Hepatitis C Undergoing Methadone Maintenance Therapy*. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 214-224.	4.7	33
215	The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. <i>Hepatology</i> , 2005, 41, 123-131.	7.3	112
216	Epidemiology and Natural History of Hepatitis C Virus Infection in Injection Drug Users: Implications for Treatment. <i>Clinical Infectious Diseases</i> , 2005, 40, S263-S269.	5.8	43

#	ARTICLE	IF	CITATIONS
217	Therapy Insight: management of hepatitis C in patients coinfecting with HIV. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 223-231.	1.7	1
218	Epoetin Alfa Once Weekly Improves Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated With Interferon/Ribavirin: A Randomized Controlled Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 504-506.	2.1	35
219	Management of the Hematologic Complications of Hepatitis C Therapy. Clinics in Liver Disease, 2005, 9, 601-616.	2.1	40
220	Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. Journal of Hepatology, 2005, 43, 78-84.	3.7	200
221	Drug-Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV-1 Protease Inhibitors. Clinical Infectious Diseases, 2004, 38, S90-S97.	5.8	186
222	Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2004, 11, 243-250.	2.0	139
223	Hepatitis C virus infection in HIV-infected patients. Current HIV/AIDS Reports, 2004, 1, 128-135.	3.1	11
224	Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology, 2004, 40, 1450-1458.	7.3	136
225	Epoetin alfa maintains hemoglobin levels in HCV-infected patients: a prospective, double-blind, randomized controlled study 1 The other PROACTIVE Study Group investigators included the following: Vijayan Balan, M.D., Mayo Clinic Scottsdale, Scottsdale, Arizona; Norbert Br��u, M.D., Bronx VA Medical Center, Bronx, New York; Robert Brown, M.D., M.P.H., NY Presbyterian Medical Center, New York, New York; William Carey, M.D., Cleveland Clinic Foundation, Cleveland, Ohio; Andrea Duchini, M.D., Baylor University School of Medicine, Dallas, Texas. Journal of Medical Virology, 2004, 76, 1316-1321.	1.3	548
226	Daily Versus Thrice-Weekly Interferon Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Persons: A Multicenter Randomized Controlled Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 464-472.	2.1	21
227	Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. Aids, 2004, 18, 2277-2284.	2.2	143
228	Care of patients with hepatitis C and HIV co-infection. Aids, 2004, 18, 1-12.	2.2	194
229	Hepatitis C in the HIV-infected patient. Clinics in Liver Disease, 2003, 7, 179-194.	2.1	50
230	Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. American Journal of Gastroenterology, 2003, 98, 2491-2499.	0.4	208
231	Hepatotoxicity Associated with Antiretroviral Therapy Containing HIV-1 Protease Inhibitors. Seminars in Liver Disease, 2003, 23, 183-194.	3.6	80
232	The Effect of HAART and HCV Infection on the Development of Hyperglycemia Among HIV-Infected Persons. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 577-584.	2.1	88
233	Hepatitis C in the HIV-Infected Person. Annals of Internal Medicine, 2003, 138, 197.	3.9	348
234	Needlestick Transmission of Hepatitis C. JAMA - Journal of the American Medical Association, 2002, 287, 2406.	7.4	98

#	ARTICLE	IF	CITATIONS
235	Hepatitis C and Progression of HIV Disease. JAMA - Journal of the American Medical Association, 2002, 288, 199.	7.4	393
236	Peginterferon-??-2a (40kD) and Ribavirin in Patients with Chronic Hepatitis C. BioDrugs, 2002, 16, 105-109.	4.6	5
237	Treatment of chronic hepatitis C: A systematic review. Hepatology, 2002, 36, S135-S144.	7.3	76
238	Hepatitis C virus infection in HIV-infected patients. Current Hepatitis Reports, 2002, 1, 16-22.	0.3	1
239	Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology, 2002, 35, 182-189.	7.3	436
240	Hepatitis C virus infection in HIV-infected patients. Current Infectious Disease Reports, 2001, 3, 469-476.	3.0	31
241	Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology, 2001, 33, 1554-1554.	7.3	54
242	Hepatitis C Virus Infection in HIV-infected Patients. Current Infectious Disease Reports, 2001, 3, 469-476.	3.0	18
243	Hepatitis C Virus Infection as an Opportunistic Disease in Persons Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases, 2000, 30, S77-S84.	5.8	244
244	Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection. JAMA - Journal of the American Medical Association, 2000, 283, 74.	7.4	822
245	The Effect of Acute Infectious Illnesses on Plasma Human Immunodeficiency Virus (HIV) Type 1 Load and the Expression of Serologic Markers of Immune Activation among HIVâ€infectected Adults. Journal of Infectious Diseases, 1998, 178, 1642-1648.	4.0	105
246	HIV and hepatitis C virus co-infection. The Hopkins HIV Report: A Bimonthly Newsletter for Healthcare Providers, 1998, 10, 8, 12.	0.0	2